Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Plans May Enrollment Start for Actemra COVID-19 Trial, Aims for Approval by Year-End
April 30, 2020
- Mitsuka to Bow Out from Mitsubishi Tanabe Board
April 30, 2020
- Bayer Japan Ethical Drug Sales Grow 4.2% in 2019
April 30, 2020
- Sanofi Japan to Ensure Drug Supplies, Employees’ Safety at the Same Time in COVID-19 Crisis: Chief
April 30, 2020
- AZ to Divest 4 Off-Patent Drugs to Taiyo Pharma
April 30, 2020
- Lilly’s 3 Tadalafil Products Transferred to Nippon Shinyaku
April 30, 2020
- Sumitomo Dainippon Ups FY2019 Guidance on Brisk North America, Japan Biz
April 30, 2020
- Takeda’s Mobocertinib Bags FDA Breakthrough Therapy Status for EGFR Exon 20 Mutant NSCLC
April 30, 2020
- Sumitomo Dainippon, Nihon Generic Pulling Some Metformin Products over Carcinogen Risks
April 28, 2020
- Daiichi Sankyo Sees 30% Growth for Edoxaban, Strong Enhertu Uptick in FY2019
April 28, 2020
- GSK, MICIN to Test Online Medical Exams and Medication Guidance for Improving Adherence in Asthma Patients
April 28, 2020
- Over 70% of Pharmacists Have “No Trouble” Getting Drug Info. Since Coronavirus Outbreak: Survey
April 28, 2020
- Keio Univ. Spinout Weighs In on AnGes' COVID-19 Vaccine Initiatives
April 28, 2020
- Shionogi Aims to Begin Clinical Studies for COVID-19 Vaccine in 2020
April 28, 2020
- Janssen Files for SC Injection of Darzalex/Vorhyaluronidase Alfa Combo for MM in Japan
April 28, 2020
- Novartis Japan Scraps Sales Offices to Boost Efficiency of Rep Activities
April 27, 2020
- AbbVie’s Rinvoq, MSD’s Noxafil Tablets Now Available
April 27, 2020
- Takeda Inks US$670 Million Divestment Deal for Europe OTC Biz
April 27, 2020
- Ohara Launches New Firm on Former Teva Takeda Site in Shiga Prefecture
April 27, 2020
- Sumitomo Dainippon, NIBIOHN Team Up on Universal Influenza Vaccine
April 27, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…